SCHEMBL23964537

SCHEMBL23964537

COc1ccc(OCCCCCCCCCCOc2cc(O)c3c(-c4ccccc4)cc(=O)oc3c2)c(-c2nc3ccccc3s2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.44
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ MAP1LC3B Q9GZQ8 1/20 0.42
▸ MAPK1 P28482 2/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MAPT P10636 5/20 0.41
▸ TP53 P04637 3/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ HCRTR1 O43613 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30109387 0.92 ALDH1A1 (0.44) ALDH1A1HDAC1HDAC2HDAC8HDAC6
SCHEMBL26172949 0.92 ALDH1A1 (0.44) ALDH1A1HDAC1HDAC2HDAC8HDAC6
SCHEMBL23964399 0.83 ALDH1A1 (0.48) ALDH1A1MAP1LC3BMAPK1MAPTTP53
SCHEMBL23964539 0.73 HDAC1 (0.41) ALDH1A1HDAC1HDAC2HDAC8HDAC6
SCHEMBL31282322 0.73 MAP1LC3B (0.59) ALDH1A1MAP1LC3BMAPK1ALOX15TSHR
SCHEMBL29474930 0.72 HDAC1 (0.56) ALDH1A1HDAC1HDAC2HDAC8HDAC6
SCHEMBL29474925 0.72 HDAC1 (0.56) ALDH1A1HDAC1HDAC2HDAC8HDAC6
SCHEMBL29474915 0.71 PPARD (0.54) ALDH1A1HDAC1HDAC2HDAC8HDAC6
SCHEMBL29474917 0.71 PPARD (0.54) ALDH1A1HDAC1HDAC2HDAC8HDAC6
SCHEMBL29474908 0.71 PPARD (0.55) ALDH1A1HDAC1HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181744-A1 COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES FUDAN UNIVERSITY (CN) 2023-06-15 — — US disclosed
US-20230181744-A1 COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES FUDAN UNIVERSITY (CN) 2023-06-15 — — US disclosed
WO-2021213518-A1 COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES 复旦大学 (CN) 2021-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181744-A1 COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES MAP1LC3B, MAP1LC3A, SQSTM1 ALDH1A1 897/4885HDAC1 254/4885HDAC2 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback